292 / 320
696
and HIV combination therapy. Lancet. 1999;353:840.
32. Hall MC, Ahmad S. Interaction between sildenafil and HIV-1
combination therapy. Lancet. 1999;353:2071–2
33. Frankel JK, Packer CD. Cushing’s syndrome due to
antiretroviral-budesonide interaction. Ann Pharmacother.
2011;45:823–4.
34. Kedem E, Shahar E, Hassoun G, Pollack S. Iatrogenic Cushing’s
syndrome due to coadministration of ritonavir and inhaled
budesonide in an asthmatic human immunodeficiency virus
infected patient. J Asthma. 2010;47:830–1.
35. Yoganathan K, David L, Williams C, Jones K. Cushing’s syndrome
with adrenal suppression induced by inhaled budesonide due
to a ritonavir drug interaction in a woman with HIV infection.
Int J STD AIDS. 2012;23:520–1.
36. Foisy MM, Yakiwchuk EM, Chiu I, Singh AE. Adrenal suppression
and Cushing’s syndrome secondary to an interaction between
ritonavir and fluticasone: A review of the literature. HIV Med.
2008;9:389–96.
37. Monahan BP, Ferguson CL, Killeavy ES, Lloyd BK, Troy J,
Cantilena Jr LR. Torsades de pointes occurring in association
with terfenadine use. JAMA. 1990;264:2788–90.
38. Rampe D, Roy ML, Dennis A, Brown AM. A mechanism for the
proarrhythmic effects of cisapride (Propulsid): High affinity
blockade of the human cardiac potassium channel HERG.
FEBS Lett. 1997;417:28–32.
39. Vadlapatla RK1, Patel M, Paturi DK, Pal D, Mitra AK. Clinically
relevant drug-drug interactions between antiretrovirals
and antifungals. Expert Opin Drug Metab Toxicol. 2014
Apr;10(4):561-80.
40. Yapa HM, Boffito M, Pozniak A. Critical Review: What Dose
of Rifabutin Is Recommended With Antiretroviral Therapy? J
Acquir Immune Defic Syndr. 2016 Jun 1;72(2):138-52.
41. Cvetkovic RS1, Goa KL. Lopinavir/ritonavir: a review of its use
in the management of HIV infection. Drugs. 2003;63(8):769-
802.
42. Ribera E, Moreno S, Viciana P, Echevarría S, Flores J, Frances
A, et al. Recomendaciones españolas sobre el uso adecuado de
enfuvirtide. Enferm Infecc Microbiol Clin. 2007;25:131–42.
43. Perry CM. Maraviroc: a review of its use in the management of
CCR5-tropic HIV-1 infection. Drugs. 2010;70:1189–213.
44. Briz V, Poveda E, Soriano V. HIV entry inhibitors: mechanisms
of action and resistance pathways. J Antimicrob Chemother.
2006;57:619–27.
45. McCormack PL. Dolutegravir: a review of its use in the
management of HIV-1 infection in adolescents and adults.
Drugs. 2014;74:1241-52.
46. Rathbun RC, Lockhart SM, Miller MM, LiedtkeMD. Dolutegravir,
a secondgeneration integrase inhibitor for the treatment of
HIV-1 infection. Ann Pharmacother. 2014;48:395-403.
47. Hicks C, Gulick RM. Raltegravir: the first HIV type 1 integrase
inhibitor. Clin Infect Dis. 2009;48:931–9.
48. Osterholzer DA1, Goldman M2. Dolutegravir: a next-
generation integrase inhibitor for treatment of HIV infection.
Clin Infect Dis. 2014 Jul 15;59(2):265-71.
49. Rathbun RC1, Lockhart SM, Miller MM, Liedtke MD.
Dolutegravir, a second-generation integrase inhibitor for the
treatment of HIV-1 infection. Ann Pharmacother. 2014 Mar;
48(3):395-403.
50. Kandel CE1, Walmsley SL2. Dolutegravir - a review of the
pharmacology, efficacy, and safety in the treatment of HIV.
Drug Des Devel Ther. 2015 Jul 7;9:3547-55.
51. Ryom L, Kirk O, Lundgren J, Reiss P, Pedersen C, De Wit S, et al.
Advanced chronic kidney disease, end-stage renal disease and
renal death among HIV-positive individuals in Europe. HIV
Med 2013; 14:503–508.
52. Mocroft A, Kirk O, Reiss P, De Wit S, Sedlacek D, Beniowski M,
et al. Estimated glomerular filtration rate, chronic kidney
disease and antiretroviral drug use in HIV-positive patients.
AIDS 2010; 24:1667–1678.
53. Ryom L, Mocroft A, Kirk O, Worm SW, Kamara DA, Reiss P, et
al. Association between antiretroviral exposure and renal
impairment among HIV-positive persons with normal base-
line renal function: the D:A:D study. J Infect Dis 2013;
207:1359–1369.
54. Scherzer R, Estrella M, Li Y, Choi AI, Deeks SG, Grunfeld C, et
al. Association of tenofovir exposure with kidney disease risk in
HIV infection. AIDS 2012; 26:867–875.
55. Campbell LJ, Ibrahim F, Fisher M, Holt SG, Hendry BM, Post FA.
Spectrum of chronic kidney disease in HIV-infected patients.
HIV Med 2009; 10:329–336.
56. Rockwood N, Mandalia S, Bower M, Gazzard B, Nelson
M. Ritonavir-boosted atazanavir exposure is associated with
an increased rate of renal stones compared with efavirenz,
ritonavir-boosted lopinavir and ritonavir-boosted darunavir.
AIDS 2011; 25:1671–1673.
57. Gallant JE, Koenig E, Andrade-Villanueva J, Chetchotisakd
P, DeJesus E, Antunes F, et al. Cobicistat versus ritonavir
as a pharmacoenhancer of atazanavir plus emtricitabine/
tenofovir disoproxil fumarate in treatment-naive HIV type
1-infected patients: week 48 results. J Infect Dis 2013; 208:
32–39.
58. Calza L, Trapani F, Salvadori C, Magistrelli E, Manfredi R,
Colangeli V, et al. Incidence of renal toxicity in HIV-infected,
antiretroviral-naive patients starting tenofovir/emtricitabine
associated with efavirenz, atazanavir/ritonavir, or lopinavir/
ritonavir. Scand J Infect Dis 2013; 45:147–154.
59. Lepist EI, Murray BP, Tong L, Roy A, Bannister R, Ray AS. Effect
of cobicistat and ritonavir on proximal renal tubular cell
uptake and efflux transporters. 51st Interscience Conference
on Antimicrobial Agents and Chemotherapy (ICAAC); 17 – 20
September 2011. Chicago. Abstract A1-1724.
60. Fernandez B, Montoya-Ferrer A, Sanz AB, Sanchez-Nino MD,
Izquierdo MC, Poveda J, et al. Tenofovir nephrotoxicity: 2011
update. AIDS Res Treat 2011; 2011: 354908.
61. Muller F, Fromm MF. Transporter-mediated drug-drug
interactions. Pharmacogenomics 2011; 12:1017–1037.
62. Hagenbuch B, Meier PJ. Organic anion transporting polypep-
tides of the OATP/SLC21 family: phylogenetic classification as
[REV. MED. CLIN. CONDES - 2016; 27(5) 682-697]